Compare AMGN & CRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMGN | CRM |
|---|---|---|
| Founded | 1980 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.7B | 217.2B |
| IPO Year | N/A | 2004 |
| Metric | AMGN | CRM |
|---|---|---|
| Price | $319.45 | $254.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 36 |
| Target Price | $315.31 | ★ $324.49 |
| AVG Volume (30 Days) | 2.8M | ★ 8.9M |
| Earning Date | 02-03-2026 | 12-03-2025 |
| Dividend Yield | ★ 3.17% | 0.63% |
| EPS Growth | ★ 65.12 | 23.36 |
| EPS | ★ 12.93 | 7.49 |
| Revenue | $35,971,000,000.00 | ★ $40,317,000,000.00 |
| Revenue This Year | $10.85 | $9.94 |
| Revenue Next Year | $1.71 | $9.01 |
| P/E Ratio | ★ $24.57 | $35.01 |
| Revenue Growth | ★ 10.56 | 8.41 |
| 52 Week Low | $253.30 | $221.96 |
| 52 Week High | $346.38 | $367.09 |
| Indicator | AMGN | CRM |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 56.88 |
| Support Level | $312.39 | $228.60 |
| Resistance Level | $320.19 | $267.90 |
| Average True Range (ATR) | 6.87 | 6.92 |
| MACD | -3.82 | 2.74 |
| Stochastic Oscillator | 25.36 | 68.90 |
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Salesforce provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.